Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen

Vaccine

Volumn 26, Issue 38, 2008, Pages 4927-4939

  Cybulski Jr , Robert J ^a   Sanz, Patrick ^a   McDaniel, Dennis ^a   Darnell, Steve ^a   Bull, Robert L ^b   O'Brien, Alison D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Bacillus anthracis; Exosporium; Spore; Vaccine

Indexed keywords

ANTHRAX VACCINE; ANTISERUM; BACTERIAL PROTEIN; PROTECTIVE ANTIGEN; PROTEIN BXPB; PROTEIN P5303; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN RECOGNITION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; IMMUNOGLOBULIN G; MACROPHAGES; MICROSCOPY, ELECTRON; RECOMBINANT PROTEINS; SPORES, BACTERIAL; TIME FACTORS;

EID: 50049111406     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.015     Document Type: Article

References (63)

1. Mock M., and Fouet A. Anthrax. Annu Rev Microbiol 55 (2001) 647-671
2. Dixon T.C., Meselson M., Guillemin J., and Hanna P.C. Anthrax. N Engl J Med 341 September (11) (1999) 815-826
3. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7 November (6) (2001) 933-944
4. Friedlander A.M., Welkos S.L., and Ivins B.E. Anthrax vaccines. Curr Top Microbiol Immunol 271 (2002) 33-60
5. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health Nations Health 52 April (4) (1962) 632-645
6. Little S.F., Ivins B.E., Fellows P.F., and Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65 December (12) (1997) 5171-5175
7. Molnar D.M., and Altenburn R.A. Alterations in the biologocal activity of protective antigen of Bacillus anthracis toxin. Proc Soc Exp Biol Med 114 November (1963) 294-297
8. Pitt M.L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87 August (2) (1999) 304
9. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 September (32) (2001) 4768-4773
10. Turnbull P.C., Leppla S.H., Broster M.G., Quinn C.P., and Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 177 5 (1988) 293-303
11. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 January (3-4) (2004) 422-430
12. Pittman P.R., Leitman S.F., Oro J.G., Norris S.L., Marano N.M., Ranadive M.V., et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 12 June (6) (2005) 713-721
13. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 May (5) (2001) 2888-2893
14. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282 December (22) (1999) 2104-2106
15. Turnbull P.C. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 13 April (2) (2000) 113-120
16. Farchaus J.W., Ribot W.J., Jendrek S., and Little S.F. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl Environ Microbiol 64 March (3) (1998) 982-991
17. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 January (2) (2005) 278-288
18. Peachman K.K., Rao M., Alving C.R., Burge R., Leppla S.H., Rao V.B., et al. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 74 January (1) (2006) 794-797
19. Sloat B.R., and Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res 23 June (6) (2006) 1217-1226
20. Ivins B., Fellows P., Pitt L., Estep J., Farchaus J., Friedlander A., et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13 December (18) (1995) 1779-1784
21. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L., Rossi C.A., Gibbs P.H., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19 April (23-24) (2001) 3241-3247
22. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 July (11-12) (1998) 1141-1148
23. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., and Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 60 February (2) (1992) 662-668
24. Welkos S.L., and Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5 August (2) (1988) 127-139
25. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 68 August (8) (2000) 4549-4558
26. Klein F., Dearmon Jr. I.A., Lincoln R.E., Mahlandt B.G., and Fernelius A.L. Immunological studies of anthrox. II. Levels of immunity against Bacillus anthracis obtained with protective antigen and live vaccine. J Immunol 88 January (1962) 15-19
27. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 May (2) (1986) 509-512
28. Shlyakhov E.N., and Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 12 June (8) (1994) 727-730
29. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 May (2) (1986) 356-363
30. Brossier F., Levy M., and Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70 February (2) (2002) 661-664
31. Gerhardt P., and Ribi E. Ultrastructure of the exosporium enveloping spores of Bacillus cereus. J Bacteriol 88 December (1964) 1774-1789
32. Steichen C., Chen P., Kearney J.F., and Turnbough Jr. C.L. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J Bacteriol 185 March (6) (2003) 1903-1910
33. Sylvestre P., Couture-Tosi E., and Mock M. A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol 45 July (1) (2002) 169-178
34. Brahmbhatt T.N., Darnell S.C., Carvalho H.M., Sanz P., Kang T.J., Bull R.L., et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 75 November (11) (2007) 5240-5247
35. Hahn U.K., Boehm R., and Beyer W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24 (2006) 4569-4571
36. Brahmbhatt T.N., Janes B.K., Stibitz E.S., Darnell S.C., Sanz P., Rasmussen S.B., et al. Bacillus anthracis exosporium protein BclA affects spore germination, interaction with extracellular matrix proteins, and hydrophobicity. Infect Immun 75 November (11) (2007) 5233-5239
37. Sanz P., Teel L.D., Alem F., Carvalho H.M., Darnell S.C., and O'Brien A.D. Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging. Infect Immun 76 March (3) (2008) 1036-1047
38. Kim H.U., and Goepfert J.M. A sporulation medium for Bacillus anthracis. J Appl Bacteriol 37 June (2) (1974) 265-267
39. Aronson A.I., and Fitz-James P. Structure and morphogenesis of the bacterial spore coat. Bacteriol Rev 40 June (2) (1976) 360-402
40. Little S.F., Leppla S.H., and Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56 July (7) (1988) 1807-1813
41. Welkos S., Friedlander A., Weeks S., Little S., and Mendelson I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 51 October (10) (2002) 821-831
42. Enkhtuya J., Kawamoto K., Kobayashi Y., Uchida I., Rana N., and Makino S. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology 152 October (Pt 10) (2006) 3103-3110
43. Redmond C., Baillie L.W., Hibbs S., Moir A.J., and Moir A. Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 150 February (Pt 2) (2004) 355-363
44. Liu H., Bergman N.H., Thomason B., Shallom S., Hazen A., Crossno J., et al. Formation and composition of the Bacillus anthracis endospore. J Bacteriol 186 January (1) (2004) 164-178
45. Read T.D., Salzberg S.L., Pop M., Shumway M., Umayam L., Jiang L., et al. Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science 296 June (5575) (2002) 2028-2033
46. Charlton S., Moir A.J., Baillie L., and Moir A. Characterization of the exosporium of Bacillus cereus. J Appl Microbiol 87 August (2) (1999) 241-245
47. Lai E.M., Phadke N.D., Kachman M.T., Giorno R., Vazquez S., Vazquez J.A., et al. Proteomic analysis of the spore coats of Bacillus subtilis and Bacillus anthracis. J Bacteriol 185 February (4) (2003) 1443-1454
48. Todd S.J., Moir A.J., Johnson M.J., and Moir A. Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium. J Bacteriol 185 June (11) (2003) 3373-3378
49. Steichen C.T., Kearney J.F., and Turnbough Jr. C.L. Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J Bacteriol 187 September (17) (2005) 5868-5876
50. Welkos S.L., Cote C.K., Rea K.M., and Gibbs P.H. A microtiter fluorometric assay to detect the germination of Bacillus anthracis spores and the germination inhibitory effects of antibodies. J Microbiol Methods 56 February (2) (2004) 253-265
51. Dixon T.C., Fadl A.A., Koehler T.M., Swanson J.A., and Hanna P.C. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell Microbiol 2 December (6) (2000) 453-463
52. Guidi-Rontani C., Weber-Levy M., Labruyere E., and Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 31 January (1) (1999) 9-17
53. Cote C.K., Rea K.M., Norris S.L., Van R.N., and Welkos S.L. The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with Bacillus anthracis spores. Microb Pathog 37 October (4) (2004) 169-175
54. Cote C.K., Van R.N., and Welkos S.L. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun 74 January (1) (2006) 469-480
55. Glomski I.J., Corre J.P., Mock M., and Goossens P.L. Cutting edge: IFN-γ-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol 178 March (5) (2007) 2646-2650
56. Cote C.K., Rossi C.A., Kang A.S., Morrow P.R., Lee J.S., and Welkos S.L. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38 May (5-6) (2005) 209-225
57. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 June (Pt 6) (2001) 1677-1685
58. Cote C.K., Bozue J., Moody K.L., Dimezzo T.L., Chapman C.E., and Welkos S.L. Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology 154 February (Pt 2) (2008) 619-632
59. Ben-Efraim S., and Liacopoulos P. Inhibition, no-effect or enhancement of immune responses following injection of mixtures of immunogenic and non-immunogenic synthetic polypeptides. Immunology 12 May (5) (1967) 517-524
60. Schechter I. Antigenic competition between polypeptidyl determinants in normal and tolerant rabbits. J Exp Med 127 February (2) (1968) 237-250
61. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72 September (9) (2004) 5383-5391
62. The Jackson Laboratory. A/J Strain Information Page; 2008. http://jaxmice.jax.org/strain/000646.html.
63. Welkos S.L., and Friedlander A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog 4 January (1) (1988) 53-69